Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach

An increase in the occurrence of viral infectious diseases is a global concern for human health. According to a WHO report, dengue virus (DENV) is one of the most common viral diseases affecting approximately 400 million people annually, with worsening symptoms in nearly 1% of cases. Both academic a...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2023-02, Vol.13, p.1061937-1061937
Main Authors: Norshidah, Harun, Leow, Chiuan Herng, Ezleen, Kamarulzaman Ezatul, Wahab, Habibah A, Vignesh, Ramachandran, Rasul, Azhar, Lai, Ngit Shin
Format: Article
Language:English
Subjects:
antiviral
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Biomarkers
Cellular and Infection Microbiology
Dengue - drug therapy
dengue virus
diagnostics
drug discovery
Humans
Molecular Targeted Therapy
NS2B/NS3pro
Protease Inhibitors - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An increase in the occurrence of viral infectious diseases is a global concern for human health. According to a WHO report, dengue virus (DENV) is one of the most common viral diseases affecting approximately 400 million people annually, with worsening symptoms in nearly 1% of cases. Both academic and industrial researchers have conducted numerous studies on viral epidemiology, virus structure and function, source and route of infection, treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia vaccine has been a major milestone in dengue treatment. However, evidence has shown that vaccines have some drawbacks and limitations. Therefore, researchers are developing dengue antivirals to curb infections. DENV NS2B/NS3 protease is a DENV enzyme essential for replication and virus assembly, making it an interesting antiviral target. For faster hit and lead recognition of DENV targets, methods to screen large number of molecules at lower costs are essential. Similarly, an integrated and multidisciplinary approach involving screening and confirmation of biological activity is required. In this review, we discuss recent strategies for searching for novel DENV NS2B/NS3 protease inhibitors from the and perspectives, either by applying one of the approaches or by integrating both. Therefore, we hope that our review will encourage researchers to integrate the best strategies and encourage further developments in this area.
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2023.1061937